Anaxsys Technology Ltd Lung Cancer Screening Device

点击翻译按钮获取中文摘要

Lung Cancer is the leading cause of cancer deaths in men and the second leading cause ofcancer deaths in women worldwide. Cancer UK reported that 43,463 people in the UK werediagnosed with lung cancer in 2011 and there were 35,371 deaths in 2012. The leading causeof lung cancer is smoking and other causes include occupational exposure to carcinogens suchas asbestos. The 5 year survival rate is 16%, largely because there is currently no screeningtool for primary care.Anaxsys has developed a novel sensor that has been shown to detect asthma and COPD inclinical studies. Early studies in COPD patients have shown that lung cancer and laryngealtumours can also be detected with this sensor, that measures breath profiles. Hence Anaxsys isdeveloping a safe, inexpensive point of care screening device that can be used by GPs toregularly screen COPD patients and smokers at their specialist COPD clinics. This test willprovide GPs with sufficient information to distinguish those patients who should be referredfor diagnostic tests at secondary care respiratory unit. Early diagnosis of lung cancer willallow surgical removal of tumours before they metastasise and spread.The objective of this project is to establish through market research whether GPs see a needfor a lung cancer screening device that can help them identify those COPD patients andsmokers who should be referred for investigation at a secondary care respiratory diagnosticclinic. The study seeks to understand the issues surrounding diagnosis of lung and respiratorytract cancers and what is required to improve the current 5 year survival rates.GPs with COPD clinics in their practices and their specialist nurses will be interviewed toestablish whether they see a need for a primary care screening tool.Interviews will be held with patients and feedback obtained on the device.Interviews will also be held with Pharmacy chains to establish whether there is a place forsuch a device in these businesses.